Evidence map›Paper›PMID 40699718›Full record

ArticleCurrent issues in molecular biology2025

Exploring the Molecular Mechanism of 1,25(OH)

Zhiyan Long, Xiangyi Wu, Tianxin Luo, Xiaomei Chen, Jian Huang, Shu Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhiyan LongCenter for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.ORCID 0009-0006-1290-9213
Xiangyi WuCenter for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.
Tianxin LuoCenter for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.
Xiaomei ChenCenter for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.
Jian HuangCenter for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.ORCID 0000-0002-1397-5670
Shu ZhangCenter for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.ORCID 0000-0001-8836-0745

Funding

2023 Subject Excellent Reserve Talent program of Affiliated Hospital of Guizhou Medical University No. gyfyxkrc-2023-12Grant from Key Lab for Chronic Disease Biomarkers of Guizhou Medical University No.2024fy004Guizhou Science and Technology Plan Project Guizhou Science Support [2021] No. 097High-level Innovative Talents in Guizhou Province gzwjrs2022-014the science and Technology Foundation of Guizhou Provincial Health and Family Planning Commission No. gzwjkj2018-1-073This work was supported by the National Natural Science Foundation of China No. 81860723, 81960589
6 · The paper itself

Abstract

Sorafenib is currently the first-line therapeutic agent for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance remains a major clinical challenge. Studies have reported that 1,25-dihydroxyvitamin D3 (1,25(OH)

Indexed as

1,25(OH)2D3autophagychemosensitivityFOXO3A/FOXM1 signaling axishepatocellular carcinoma sorafenib resistancenetwork pharmacology

Identifiers

PMID40699718
PMCPMC12109729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.